Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries February 2, 2011 Lexington, MA -- Concert Pharmaceuticals, Inc. today announced that it has entered into a …
News
Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics´ Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
—In Vitro Results Published in Journal of Immunotherapy Demonstrate That Potency of Mature CD40L RNA Electroporated DCs Correlates with IL-12 Secretion by Tracking Multifunctional CD8(+)/CD28(+) …
CyDex Pharmaceuticals Approves Merger with Ligand Pharmaceuticals
Transaction Closed Today Expected to Accelerate Development of CyDex’s Captisol® Franchise LENEXA, Kansas – January 26, 2011 – CyDex Pharmaceuticals, Inc. today announced that its stockholders have …
MediGene Adds Romania and Bulgaria to Existing Partnership Agreement with Meditrina for the Commercialization of Veregen®
Martinsried/Munich, January 25, 2011. The biotech company MediGene AG (Frankfurt, Prime Standard) announced today that its existing partnership with Meditrina Pharmaceuticals Ltd., Greece, for the …
WILEX announces start of interim analysis for its Phase III ARISER registration trial with RENCAREX®
Munich, Germany, 24 January, 2011. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced the achievement of a major clinical milestone. Over 340 recurrences have now been …
Evotec AG – Collaboration with Takeda Cambridge for Multi-target Hit Identification
Hamburg, Germany - 20 January 2011: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule …